Roche enlists Monte Rosa for cancer, neuro discovery deal with $50M upfront
Roche is forging a new partnership with a startup focused on protein degradation.
The multinational pharma company announced Tuesday it is paying $50 million upfront to team up with Monte Rosa Therapeutics and its slate of “molecular glue” programs that it argues can target proteins central to the degradation process. If everything comes to fruition, Roche could end up spending more than $2 billion in downstream biobucks, according to a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.